Physician profile
Bryan Fix
NPI 1982213997
$690.88
in general payments reported to CMS, 2019-2025
15 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.82 · 2024: $461 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $149.41 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $121.68 | 2024-2025 | |
| Exact Sciences Corporation | $99.87 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $61.73 | 2024 | Prolia, Evenity, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.82 | 2021 | |
| Genzyme Corporation | $29.87 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.74 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.60 | 2024 | Xifaxan |
| Shield Therapeutics INC | $24.24 | 2024 | |
| Merck Sharp & Dohme LLC | $23.09 | 2024 | Gardasil, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $22.12 | 2024 | Eliquis |
| Lilly USA, LLC | $19.93 | 2024 | Mounjaro, Zepbound |
| Intra-Sana Laboratories | $15.84 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Abbvie INC. | $15.00 | 2025 | |
| Lucid Diagnostics INC. | $14.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Fix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.